Acadia Healthcare’s third quarter results drew a significant positive market reaction, as the company surpassed Wall Street’s revenue and profit expectations. Management attributed the performance to strong growth in patient volumes, effective cost controls, and accelerated operational milestones for new facilities. CEO Debbie Osteen highlighted the impact of recently opened acute care sites and operational improvements at legacy locations, emphasizing that “solid growth in patient volumes and strong revenue per patient day” were central to the quarter’s outcome.
Is now the time to buy ACHC? Find out in our full research report (it’s free for active Edge members).
Acadia Healthcare (ACHC) Q3 2026 highlights:
- Revenue $895.3 million vs S&P analysts’ estimates of $877.6 million (5.1% year-on-year growth, 2% beat)
- Adjusted EPS $0.60 vs S&P analysts’ estimates of $0.46 (29.2% beat)
- Adjusted EBITDA $176.4 million vs analyst estimates of $161.6 million (19.7% margin, 9.2% beat)
- Revenue guidance The company slightly lifted its revenue guidance for the full year to $3.45 billion at the midpoint from $3.43 billion
- Adjusted EPS guidance Management raised its full-year adjusted EPS guidance to $1.75 at the midpoint, a 14.8% increase
- EBITDA guidance $620 million at the midpoint for the full year, above analyst estimates of $602.8 million
- Operating margin 10.5%, up from 9% in the same quarter last year
- Sales volumes rose 9.7% year on year (3.2% in the same quarter last year)
- Market capitalization $3.23 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our top 5 analyst questions from Acadia Healthcare’s Q3 earnings call
- AJ Rice (UBS) asked about the company’s remaining opportunities to fully recover and return to its potential earnings trajectory. CEO Debbie Osteen emphasized operational discipline, legacy facility growth, and ongoing cost controls as key levers for further improvement.
- Ben Hendrix (RBC Capital Markets) requested clarification on reduced capital expenditures. CFO David Duckworth explained that lower CapEx is due to fewer new facility projects, with future spending focused on existing site upgrades and maintenance.
- Brian Tanquilut (Jefferies) questioned whether stabilized CTC and specialty revenue marks a base for future growth. Osteen replied that recent admissions trends are encouraging, and regional strategies are aimed at reigniting growth across these service lines.
- Matthew Gillmor (KeyBanc Capital Markets) probed on bad debt and payer denial moderation. Duckworth pointed to revenue cycle improvements and technology investments, stating that headwinds have become “nominal” and are being actively managed.
- Ann Hynes (Mizuho) inquired about the impact of new Medicaid work requirements. Osteen responded that about half of Acadia’s Medicaid patients are in expansion states, and most are expected to be exempt from work requirements, limiting potential impact.
Catalysts in upcoming quarters
Going forward, the StockStory team is monitoring (1) the ramp-up pace and financial contribution of new acute facilities as they scale occupancy, (2) operational efficiency and cost management efforts, particularly in underperforming segments, and (3) the outcome of pending supplemental payment programs in Florida and Ohio. Execution in these areas will be critical to sustaining improved profitability and meeting raised financial guidance.
Acadia Healthcare currently trades at $33.75, up from $32.25 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
High-quality stocks for all market conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
